Update on Rituximab: An Established Treatment for All Immune-Mediated Kidney Diseases?
Nephron Clinical Practice · 26.03.2014 · 126 (3) · 97-109
DOI: 10.1159/000358887 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephron Clinical Practice, online erschienen am 26.03.2014. Verfasst von Rhys Evans und 1 weiteren Autor:innen. Beteiligte Einrichtung: UCL Centre for Nephrology, Royal Free Hospital, London, UK. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Rituximab, a monoclonal antibody directed against the CD20 antigen, found on certain B-cell subsets, results in significant B-cell depletion and has been increasingly used in immune-mediated renal disease and transplantation. Although originally applied to what were considered antibody-mediated diseases, it has become clear that auto- and alloreactive B cells contribute in many ways to immune dysfunction, and the benefit of B-cell depletion extends beyond reduction in auto- or alloantibody levels. Most positive data regarding the benefit of rituximab in immune-mediated kidney disease have come from uncontrolled cohort studies, with the only positive controlled clinical trials demonstrating efficacy for the treatment of systemic vasculitis. While negative trials may have potentially missed clinical effects due to trial design, there may be significant differences in responses in different diseases or lack of efficacy due to therapeutic overlap when used with certain drug combinations. Rituximab is a novel treatment that provides a clear alternative for patients in different clinical situations, and allows for customization of therapy. However, much remains to be understood as to how best to use it in a cost-effective manner, when not to use it, and what the long-term impact of therapy may be.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UCL Centre for Nephrology, Royal Free Hospital, London, UK.
Zitieren
APA
Evans, R., & Salama, A. D. (2014). Update on Rituximab: An Established Treatment for All Immune-Mediated Kidney Diseases?. Nephron Clinical Practice, 126(3), 97-109. https://doi.org/10.1159/000358887
Vancouver
Evans R, Salama AD. Update on Rituximab: An Established Treatment for All Immune-Mediated Kidney Diseases?. Nephron Clinical Practice. 2014;126(3):97-109. doi:10.1159/000358887
BibTeX
@article{Evans2014,
author = {Evans, Rhys and Salama, Alan D},
title = {Update on Rituximab: An Established Treatment for All Immune-Mediated Kidney Diseases?},
journal = {Nephron Clinical Practice},
year = {2014},
volume = {126},
number = {3},
pages = {97--109},
doi = {10.1159/000358887}
}
EUVIMED